BIO-Europe Spring® 2014: Are big biotechs the better dealmakers?

March 25, 2014
In deciding whether to partner with pharma or big biotech, which one is the better dealmaker? A few key factors to consider when making this decision include: cash; the probability of technical success, or PTS; value creation; and liquidity. According to James Sabry of Genentech, the most important consideration is the PTS. Listen in as the panelists weigh the pros and cons of pharma vs. big biotech, and how to find the right strategic fit. For more information on BIO-Europe Spring, visit our webpage: http://www.ebdgroup.com/bes/index.php Please view the rest of the video at http://www.partnering360.com/insight/showroom/id/471
Previous Video
BIO-Europe Spring® 2014: Asset-centric companies: Still lean and mean or "so 2012"?
BIO-Europe Spring® 2014: Asset-centric companies: Still lean and mean or "so 2012"?

During the financial drought, new financing structures surfaced in biotech, resulting in lean and asset-cen...

Next Video
ChinaBio Partnering Forum attracts global life science leaders
ChinaBio Partnering Forum attracts global life science leaders

ChinaBio Partnering forum is the premier life science partnering event in China attracting biotech and phar...